华兰生物(002007) - 2020 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2020 was ¥677,541,355.35, a decrease of 2.62% compared to ¥695,786,897.01 in the same period last year[3]. - The net profit attributable to shareholders was ¥247,286,426.50, down 4.71% from ¥259,506,104.27 year-on-year[3]. - The net profit after deducting non-recurring gains and losses was ¥243,809,415.41, an increase of 1.49% compared to ¥240,220,781.73 in the previous year[3]. - The basic earnings per share were ¥0.1762, down 4.76% from ¥0.1850 year-on-year[3]. - The total comprehensive income for the period was CNY 237.43 million, compared to CNY 254.61 million in the previous year, reflecting a decline of 6.7%[28]. - The total profit for the period was CNY 152.80 million, an increase of 30.5% compared to CNY 117.00 million in the previous year[30]. Cash Flow - The net cash flow from operating activities was ¥95,887,096.67, a significant decrease of 49.03% from ¥188,118,276.43 in the same period last year[3]. - The company's cash flow from operating activities was CNY 568.10 million, a decrease of 29.0% from CNY 798.90 million in the same period last year[32]. - Cash received from sales of goods and services was ¥225,055,585.85, down 31.3% from ¥327,368,860.01 in the previous year[35]. - The net cash flow from financing activities was ¥53,695,247.10, an increase from ¥47,900,076.49 in the same period last year[34]. - The ending balance of cash and cash equivalents was ¥359,519,051.88, compared to ¥308,483,918.02 at the end of Q1 2019[34]. Assets and Liabilities - The total assets at the end of the reporting period were ¥7,791,312,700.57, an increase of 2.74% from ¥7,583,197,994.71 at the end of the previous year[3]. - The total liabilities were CNY 666,104,639.73 as of March 31, 2020, down from CNY 699,256,000.55 at the end of December 2019[19]. - The total equity attributable to the parent company reached CNY 6,794,251,046.01 as of March 31, 2020, compared to CNY 6,543,127,592.63 at the end of December 2019[20]. - Cash and cash equivalents increased to CNY 537,295,290.32 from CNY 417,421,654.58, indicating improved liquidity[21]. - Accounts receivable rose significantly to CNY 354,642,144.54 from CNY 183,520,874.00, suggesting increased sales or credit terms[21]. - Inventory decreased to CNY 460,551,504.40 from CNY 574,243,029.78, which may indicate better inventory management[21]. Shareholder Information - The company reported a total of 59,443 common shareholders at the end of the reporting period[6]. - The top shareholder, Chongqing Shengkang Biotechnology Development Co., Ltd., held 15.05% of the shares, totaling 211,106,676 shares[6]. Expenses - Sales expenses decreased by 55.20% compared to the same period last year, mainly due to a reduction in promotional consulting fees[11]. - Financial expenses decreased by 165.20% compared to the same period last year, primarily due to an increase in interest income during the period[11]. - The company experienced a significant reduction in sales expenses, which dropped to CNY 15.55 million from CNY 58.73 million year-over-year, a decrease of 73.5%[29]. - Research and development expenses increased significantly to CNY 20.21 million, up 155.5% from CNY 7.92 million in the same period last year[29]. Other Financial Metrics - The weighted average return on net assets was 3.71%, down 0.87% from 4.58% in the same period last year[3]. - The company reported a net investment income of CNY 14,633,617.69, slightly down from CNY 15,822,928.62 in the previous period[25]. - The company reported a decrease in financial asset impairment losses, with a loss of CNY 5.43 million compared to no losses reported in the previous year[30]. Additional Information - The first quarter report was not audited[38]. - The company is focusing on cost control and efficiency improvements to enhance profitability in the upcoming quarters[24].